Literature DB >> 28838028

Distinct in vivo target occupancy by bivalent- and induced-fit-like binding drugs.

Georges Vauquelin1.   

Abstract

BACKGROUND AND
PURPOSE: Optimal drug therapy often requires long-lasting target occupancy While this attribute was usually linked to the drug's pharmacokinetic properties, the dissociation rate is now increasingly recognized to contribute as well. Nearly all the earlier pharmacokinetic-pharmacodynamic (PK-PD) simulations encompassed single-step binding drugs and focused on koff . However, 'micro'-PK mechanisms and more complex binding mechanisms like bivalent- and induced-fit binding may contribute as well. Corresponding binding models are presently explored. EXPERIMENTAL APPROACH: We compared the 24 h in vivo occupancy over time profiles of prototype bivalent- and induced-fit-like binding drugs (A and B) after one or repeated daily dosings, both without and with rebinding. Special attention was focused on the effect of each of the microscopic rate constants on the occupancy profiles and on the metrics to represent those profiles. KEY
RESULTS: Although both models can be represented by the same mathematical formulation, drugs A and B display quite different occupancy profiles, even though they have the same potency. These differences can be attributed to the different effects of their microscopic rate constants on their composite koff and also on their susceptibility to experience rebinding. This also affects how the occupancy profiles of bivalent- and induced-fit-like binders progress when repeating the dosings and by changing the dosage. CONCLUSIONS AND IMPLICATIONS: Closer attention should be paid to more complex binding models in PK-PD simulations. This may help pharmacologists and medicinal chemists to improve the translation of in vitro kinetic measurements from preclinical screening programmes into clinical efficiency.
© 2017 The British Pharmacological Society.

Mesh:

Substances:

Year:  2017        PMID: 28838028      PMCID: PMC5715606          DOI: 10.1111/bph.13989

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  53 in total

Review 1.  On the different experimental manifestations of two-state 'induced-fit' binding of drugs to their cellular targets.

Authors:  Georges Vauquelin; Isabelle Van Liefde; David C Swinney
Journal:  Br J Pharmacol       Date:  2016-03-15       Impact factor: 8.739

Review 2.  Drug-target residence time--a case for G protein-coupled receptors.

Authors:  Dong Guo; Julia M Hillger; Adriaan P IJzerman; Laura H Heitman
Journal:  Med Res Rev       Date:  2014-02-18       Impact factor: 12.944

Review 3.  Drug-target residence time and its implications for lead optimization.

Authors:  Robert A Copeland; David L Pompliano; Thomas D Meek
Journal:  Nat Rev Drug Discov       Date:  2006-08-04       Impact factor: 84.694

4.  Hybrid bombesin analogues: combining an agonist and an antagonist in defined distances for optimized tumor targeting.

Authors:  Carsten Kroll; Rosalba Mansi; Friederike Braun; Stefanie Dobitz; Helmut R Maecke; Helma Wennemers
Journal:  J Am Chem Soc       Date:  2013-10-31       Impact factor: 15.419

5.  Conformational adaptation in drug-target interactions and residence time.

Authors:  Robert A Copeland
Journal:  Future Med Chem       Date:  2011-09       Impact factor: 3.808

6.  Pharmacodynamics: Which trails are your drugs taking?

Authors:  Rumin Zhang
Journal:  Nat Chem Biol       Date:  2015-04-20       Impact factor: 15.040

7.  The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy and safety.

Authors:  Robert A Copeland
Journal:  Expert Opin Drug Discov       Date:  2010-04       Impact factor: 6.098

8.  Effects of target binding kinetics on in vivo drug efficacy: koff , kon and rebinding.

Authors:  Georges Vauquelin
Journal:  Br J Pharmacol       Date:  2016-07-04       Impact factor: 8.739

Review 9.  Cell membranes… and how long drugs may exert beneficial pharmacological activity in vivo.

Authors:  Georges Vauquelin
Journal:  Br J Clin Pharmacol       Date:  2016-05-29       Impact factor: 4.335

10.  The Concise Guide to PHARMACOLOGY 2015/16: Overview.

Authors:  Stephen Ph Alexander; Eamonn Kelly; Neil Marrion; John A Peters; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Christopher Southan; O Peter Buneman; William A Catterall; John A Cidlowski; Anthony P Davenport; Doriano Fabbro; Grace Fan; John C McGrath; Michael Spedding; Jamie A Davies
Journal:  Br J Pharmacol       Date:  2015-12       Impact factor: 8.739

View more
  5 in total

1.  Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen.

Authors:  Eleanor Jing Yi Cheong; Pramod C Nair; Rebecca Wan Yi Neo; Ho Thanh Tu; Fu Lin; Edmund Chiong; Kesavan Esuvaranathan; Hao Fan; Russell Z Szmulewitz; Cody J Peer; William D Figg; Christina Li Lin Chai; John O Miners; Eric Chun Yong Chan
Journal:  J Pharmacol Exp Ther       Date:  2020-06-17       Impact factor: 4.030

Review 2.  Link between a high k on for drug binding and a fast clinical action: to be or not to be?

Authors:  Georges Vauquelin
Journal:  Medchemcomm       Date:  2018-08-16       Impact factor: 3.597

3.  Induced fit versus conformational selection: From rate constants to fluxes… and back to rate constants.

Authors:  Georges Vauquelin; Dominique Maes
Journal:  Pharmacol Res Perspect       Date:  2021-10

4.  Utilizing the Combination of Binding Kinetics and Micro-Pharmacokinetics Link in Vitro α-Glucosidase Inhibition to in Vivo Target Occupancy.

Authors:  Guopeng Wang; Yanhua Ji; Xueyan Li; Qian Wang; Hang Gong; Baoshun Wang; Yang Liu; Yanli Pan
Journal:  Biomolecules       Date:  2019-09-16

5.  Evidence for Two Modes of Binding of the Negative Allosteric Modulator SB269,652 to the Dopamine D2 Receptor.

Authors:  Richard Ågren; Kristoffer Sahlholm
Journal:  Biomedicines       Date:  2021-12-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.